Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis.
Recent clinical trials have established B cell depletion by the anti-CD20 chimeric antibody Rituximab as a beneficial therapy for patients with relapsing-remitting multiple sclerosis (MS). The impact of Rituximab on T cell responses remains largely unexplored. In the experimental autoimmune encephal...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2011-02-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21359213/?tool=EBI |
| _version_ | 1819036807221739520 |
|---|---|
| author | Nancy L Monson Petra Cravens Rehana Hussain Christopher T Harp Matthew Cummings Maria de Pilar Martin Li-Hong Ben Julie Do Jeri-Anne Lyons Amy Lovette-Racke Anne H Cross Michael K Racke Olaf Stüve Mark Shlomchik Todd N Eagar |
| author_facet | Nancy L Monson Petra Cravens Rehana Hussain Christopher T Harp Matthew Cummings Maria de Pilar Martin Li-Hong Ben Julie Do Jeri-Anne Lyons Amy Lovette-Racke Anne H Cross Michael K Racke Olaf Stüve Mark Shlomchik Todd N Eagar |
| author_sort | Nancy L Monson |
| collection | DOAJ |
| description | Recent clinical trials have established B cell depletion by the anti-CD20 chimeric antibody Rituximab as a beneficial therapy for patients with relapsing-remitting multiple sclerosis (MS). The impact of Rituximab on T cell responses remains largely unexplored. In the experimental autoimmune encephalomyelitis (EAE) model of MS in mice that express human CD20, Rituximab administration rapidly depleted peripheral B cells and strongly reduced EAE severity. B cell depletion was also associated with diminished Delayed Type Hypersensitivity (DTH) and a reduction in T cell proliferation and IL-17 production during recall immune response experiments. While Rituximab is not considered a broad immunosuppressant, our results indicate a role for B cells as a therapeutic cellular target in regulating encephalitogenic T cell responses in specific tissues. |
| first_indexed | 2024-12-21T08:11:23Z |
| format | Article |
| id | doaj.art-7eb457a109ad42ca8f3e5a28c0d1260d |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-21T08:11:23Z |
| publishDate | 2011-02-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-7eb457a109ad42ca8f3e5a28c0d1260d2022-12-21T19:10:40ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-02-0162e1710310.1371/journal.pone.0017103Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis.Nancy L MonsonPetra CravensRehana HussainChristopher T HarpMatthew CummingsMaria de Pilar MartinLi-Hong BenJulie DoJeri-Anne LyonsAmy Lovette-RackeAnne H CrossMichael K RackeOlaf StüveMark ShlomchikTodd N EagarRecent clinical trials have established B cell depletion by the anti-CD20 chimeric antibody Rituximab as a beneficial therapy for patients with relapsing-remitting multiple sclerosis (MS). The impact of Rituximab on T cell responses remains largely unexplored. In the experimental autoimmune encephalomyelitis (EAE) model of MS in mice that express human CD20, Rituximab administration rapidly depleted peripheral B cells and strongly reduced EAE severity. B cell depletion was also associated with diminished Delayed Type Hypersensitivity (DTH) and a reduction in T cell proliferation and IL-17 production during recall immune response experiments. While Rituximab is not considered a broad immunosuppressant, our results indicate a role for B cells as a therapeutic cellular target in regulating encephalitogenic T cell responses in specific tissues.https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21359213/?tool=EBI |
| spellingShingle | Nancy L Monson Petra Cravens Rehana Hussain Christopher T Harp Matthew Cummings Maria de Pilar Martin Li-Hong Ben Julie Do Jeri-Anne Lyons Amy Lovette-Racke Anne H Cross Michael K Racke Olaf Stüve Mark Shlomchik Todd N Eagar Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis. PLoS ONE |
| title | Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis. |
| title_full | Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis. |
| title_fullStr | Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis. |
| title_full_unstemmed | Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis. |
| title_short | Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis. |
| title_sort | rituximab therapy reduces organ specific t cell responses and ameliorates experimental autoimmune encephalomyelitis |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21359213/?tool=EBI |
| work_keys_str_mv | AT nancylmonson rituximabtherapyreducesorganspecifictcellresponsesandamelioratesexperimentalautoimmuneencephalomyelitis AT petracravens rituximabtherapyreducesorganspecifictcellresponsesandamelioratesexperimentalautoimmuneencephalomyelitis AT rehanahussain rituximabtherapyreducesorganspecifictcellresponsesandamelioratesexperimentalautoimmuneencephalomyelitis AT christophertharp rituximabtherapyreducesorganspecifictcellresponsesandamelioratesexperimentalautoimmuneencephalomyelitis AT matthewcummings rituximabtherapyreducesorganspecifictcellresponsesandamelioratesexperimentalautoimmuneencephalomyelitis AT mariadepilarmartin rituximabtherapyreducesorganspecifictcellresponsesandamelioratesexperimentalautoimmuneencephalomyelitis AT lihongben rituximabtherapyreducesorganspecifictcellresponsesandamelioratesexperimentalautoimmuneencephalomyelitis AT juliedo rituximabtherapyreducesorganspecifictcellresponsesandamelioratesexperimentalautoimmuneencephalomyelitis AT jeriannelyons rituximabtherapyreducesorganspecifictcellresponsesandamelioratesexperimentalautoimmuneencephalomyelitis AT amylovetteracke rituximabtherapyreducesorganspecifictcellresponsesandamelioratesexperimentalautoimmuneencephalomyelitis AT annehcross rituximabtherapyreducesorganspecifictcellresponsesandamelioratesexperimentalautoimmuneencephalomyelitis AT michaelkracke rituximabtherapyreducesorganspecifictcellresponsesandamelioratesexperimentalautoimmuneencephalomyelitis AT olafstuve rituximabtherapyreducesorganspecifictcellresponsesandamelioratesexperimentalautoimmuneencephalomyelitis AT markshlomchik rituximabtherapyreducesorganspecifictcellresponsesandamelioratesexperimentalautoimmuneencephalomyelitis AT toddneagar rituximabtherapyreducesorganspecifictcellresponsesandamelioratesexperimentalautoimmuneencephalomyelitis |